NasdaqGS - Nasdaq Real Time Price • USD
Vertex Pharmaceuticals Incorporated (VRTX)
As of 9:42 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 21 | 20 | 25 | 23 |
| Avg. Estimate | 4.04 | 4.12 | 16.72 | 18.16 |
| Low Estimate | 3.61 | 3.77 | 15.32 | 14.75 |
| High Estimate | 4.44 | 4.5 | 18.29 | 20.54 |
| Year Ago EPS | 3.05 | 3.89 | 15.23 | 16.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 22 | 22 | 30 | 29 |
| Avg. Estimate | 2.58B | 2.65B | 10.7B | 11.7B |
| Low Estimate | 2.44B | 2.61B | 10.6B | 10.98B |
| High Estimate | 2.63B | 2.7B | 10.91B | 13.12B |
| Year Ago Sales | 2.34B | 2.49B | 9.87B | 10.7B |
| Sales Growth (year/est) | 10.20% | 6.10% | 8.40% | 9.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 3 | 3.88 | 3.97 | 4.1 |
| EPS Actual | 3.05 | 3.89 | 4.08 | 4.2 |
| Difference | 0.05 | 0.01 | 0.11 | 0.1 |
| Surprise % | 1.70% | 0.30% | 2.80% | 2.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 4.04 | 4.12 | 16.72 | 18.16 |
| 7 Days Ago | 4.04 | 4.1 | 16.62 | 18.17 |
| 30 Days Ago | 4.05 | 4.13 | 16.78 | 18.35 |
| 60 Days Ago | 4.03 | 4.12 | 16.74 | 18.31 |
| 90 Days Ago | 4.05 | 4.14 | 16.36 | 17.97 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | 3 | 3 | 1 |
| Up Last 30 Days | 3 | 3 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 2 | 3 | 6 |
Growth Estimates
| CURRENCY IN USD | VRTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 32.50% | -- | -- | 0.80% |
| Next Qtr. | 5.90% | -- | -- | 9.60% |
| Current Year | 9.80% | -- | -- | 4.50% |
| Next Year | 8.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 12.80% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 29.84% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Guggenheim: Buy to Buy | 4/18/2024 |
| Maintains | UBS: Buy to Buy | 4/17/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/15/2024 |
| Maintains | Canaccord Genuity: Sell to Sell | 4/12/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/11/2024 |
| Upgrade | Evercore ISI Group: In-Line to Outperform | 4/11/2024 |
Related Tickers
ALPN Alpine Immune Sciences, Inc.
64.42
-0.02%
REGN Regeneron Pharmaceuticals, Inc.
903.44
+1.06%
CRSP CRISPR Therapeutics AG
57.18
+1.82%
VERA Vera Therapeutics, Inc.
39.49
+0.04%
VKTX Viking Therapeutics, Inc.
64.32
-0.55%
JANX Janux Therapeutics, Inc.
47.66
-2.44%
NVO Novo Nordisk A/S
123.78
+0.84%
NTLA Intellia Therapeutics, Inc.
21.39
+0.33%
MRNA Moderna, Inc.
103.00
+0.98%
ADIL Adial Pharmaceuticals, Inc.
2.1001
-3.21%